Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT01824875 · View on ClinicalTrials.gov ↗
Study Summary
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG temozolomide
- DRUG capecitabine
Study Locations (20)
California
- Kaiser Anaheim Medical Center — Anaheim
- Kaiser Permanente-Deer Valley Medical Center — Antioch
- Kaiser Permanente Medical Group - Baldwin Park — Baldwin Park
- Kaiser Foundation Hospital — Bellflower
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley
- Mills - Peninsula Hospitals — Burlingame
- Kaiser Permanente Hospital — Fontana
- Kaiser Permanente, Fremont — Fremont
- Kaiser Permanente — Fresno
- Kaiser Permanente - Harbor City — Harbor City
- Kaiser Permanente, Hayward — Hayward
- Southern California Permanente Medical Group — Irvine
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- University of Southern California/Norris Cancer Center — Los Angeles
- Kaiser Permanente-West Los Angeles — Los Angeles
- Cedars-Sinai Medical Center — Los Angeles
- Kaiser Permanente-Modesto — Modesto
- Sutter Cancer Research Consortium — Novato
- Kaiser Permanente-Oakland — Oakland
- University of California Medical Center At Irvine-Orange Campus — Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2013-08-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824875
The ClinicalTrials.gov registry entry for NCT01824875 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Insulinoma appearing as the primary indexed condition, and to 2 interventions — of which temozolomide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01824875 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01824875 about?
NCT01824875 is a clinical study titled "Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors". This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, eit...
What is the current status of trial NCT01824875?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2013-08-08. Estimated completion is 2026-12.
What conditions does trial NCT01824875 study?
This clinical trial studies the following conditions: Insulinoma, Gastrinoma, Glucagonoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01824875?
The interventions under investigation include: temozolomide (DRUG), capecitabine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01824875?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01824875 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.